COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - share repurchase programme
09/02/2026
Bagsværd, Denmark, 9 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Axe Compute Appoints Christopher Miglino as Chief Executive Officer, Ushering in a New Era of Decentralized Compute
09/02/2026
PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Axe Compute (or the “Company”) (Nasdaq: AGPU) today announced the appointment of Christopher Miglino as Chief Executive Officer, marking a pivotal development in the company [...]
Context Therapeutics to Participate in Upcoming Investor Conferences
09/02/2026
PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
09/02/2026
TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the University of Calgary [...]
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
09/02/2026
PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by [...]
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
09/02/2026
DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
09/02/2026
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita [...]
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
09/02/2026
NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune [...]
Kraig Biocraft Laboratories Poised for Explosive Spider Silk Production Growth
09/02/2026
2026 Production Plan Set for a Record 10 Metric Tons of Recombinant Spider Silk Cocoon Per Month ANN ARBOR, Mich., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig [...]
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
09/02/2026
Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today [...]
Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria
09/02/2026
Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO ® and ALOXI ® to Austria Lugano, Switzerland – February 9th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global [...]
Avis aux médias : La journée Tout le monde en rouge attire l’attention sur la crise des maladies cardiaques chez les femmes au Canada
09/02/2026
OTTAWA, Ontario, 09 févr. 2026 (GLOBE NEWSWIRE) -- Le 13 février, la population canadienne célébrera la Journée Tout le monde en rouge , une campagne nationale de sensibilisation à la santé cardiaque des femmes. [...]
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
09/02/2026
Company to host a webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company [...]
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
09/02/2026
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
09/02/2026
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the [...]
Media Advisory: Wear Red Canada highlights heart disease crisis facing Canadian women
09/02/2026
OTTAWA, Ontario, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Canadians will mark Wear Red Canada Day on February 13, a national awareness initiative focused on women’s heart health. Why: Heart disease is the leading cause of [...]
Aerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to Systemically Deliver RNA Medicines to the Brain
09/02/2026
Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025 Appoints Arno de Wilde, Philip Scheltens and Alex Colville to its Board of Directors DUBLIN and LONDON, [...]
BioSyent to Acquire Oral Science Inc.
09/02/2026
Accretive Transaction with Combined Companies’ Pro-Forma Revenue in Excess of $70.00 Million and EBITDA (1) in Excess of $15.75 Million (TTM Sept 30, 2025) MISSISSAUGA, Ontario, Feb. 09, 2026 (GLOBE NEWSWIRE) -- [...]
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
09/02/2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the [...]

Pages